Literature DB >> 12297910

Pattern and incidence of first site recurrences following sentinel node procedure in melanoma patients.

Markwin G Statius Muller1, Paul A M van Leeuwen, Paul J van Diest, Rik Pijpers, Robert J Nijveldt, Ronald J C L M Vuylsteke, Sybren Meijer.   

Abstract

Studies of large series of melanoma patients indicated that the average incidence of developing a recurrence during follow-up was 40%. The most frequent first sites of these recurrences were the regional lymph nodes. We hypothesized that the sentinel node (SN) procedure may change the pattern of recurrence by reducing the number of first recurrences in the regional lymph node basin during follow-up to a negligible number, and that locoregional cutaneous and distance metastases are the major future sites of recurrence. We further studied the influence of SN status together with different influential factors on prognosis. An SN procedure with a triple technique was performed in 250 consecutive patients with proven AJCC stages I and II cutaneous melanoma. The median follow-up was 38 months. So far, 44 patients (18%) have developed a recurrence of the disease. The distribution of localization of the first metastases was as follows: 23 patients (52%) with a locoregional cutaneous recurrence; 4 (9%) with recurrence in the regional lymph node basin; 2 (5%) with recurrence in an interval node; and 15 (34%) with distant recurrence. The relative risk of developing recurrence for SN-positive patients is 4.2; for Breslow thickness of 1.51 to 4.00 mm it is 5.5, and thicker than 4.0 mm it is 6.2; for lymphatic invasion 7.6; and for ulceration 3.8. We conclude that the SN procedure changes the pattern of recurrences during follow-up by reducing the number of first recurrences within the regional lymph node basin to a negligible number. High Breslow thickness, lymphatic invasion, and ulceration of the primary melanoma are strong risk factors for recurrence.

Entities:  

Mesh:

Year:  2002        PMID: 12297910     DOI: 10.1007/s00268-002-6197-8

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

1.  Recurrent malignant melanoma: the identification of prognostic factors to predict survival.

Authors:  D S Reintgen; C Cox; C L Slingluff; H F Seigler
Journal:  Ann Plast Surg       Date:  1992-01       Impact factor: 1.539

2.  Results of treatment of 269 patients with primary cutaneous melanoma: a five-year prospective study.

Authors:  T K Gupta
Journal:  Ann Surg       Date:  1977-08       Impact factor: 12.969

Review 3.  Malignant melanoma: Mayo Clinic experience.

Authors:  F H Sim; T E Nelson; D J Pritchard
Journal:  Mayo Clin Proc       Date:  1997-06       Impact factor: 7.616

Review 4.  Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies.

Authors:  J M Kirkwood
Journal:  Eur J Cancer       Date:  1998-07       Impact factor: 9.162

5.  Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patients.

Authors:  H Drepper; C O Köhler; B Bastian; H Breuninger; E B Bröcker; J Göhl; W Groth; P Hermanek; W Hohenberger; A Lippold
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

6.  Prognosis of clinical stage I melanoma patients with positive elective regional node dissection.

Authors:  H K Koh; A J Sober; C L Day; R A Lew; A W Kopf; W Lamar; A Ben Cosimi; W C Wood; M C Mihm; R A Malt
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

7.  Elective lymph node dissection in patients with primary melanoma of the trunk and limbs treated at the Sydney Melanoma unit from 1960 to 1991.

Authors:  A S Coates; C I Ingvar; K Petersen-Schaefer; H M Shaw; G W Milton; C J O'Brien; J F Thompson; W H McCarthy
Journal:  J Am Coll Surg       Date:  1995-04       Impact factor: 6.113

8.  The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51-3.99 mm).

Authors:  D E Elder; D Guerry; M VanHorn; S Hurwitz; L Zehngebot; L I Goldman; D LaRossa; R Hamilton; E E Bondi; W H Clark
Journal:  Cancer       Date:  1985-07-15       Impact factor: 6.860

9.  Prognostic parameters in recurrent malignant melanoma.

Authors:  C P Karakousis; D F Temple; R Moore; J L Ambrus
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

10.  Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients.

Authors:  M M Urist; W A Maddox; J E Kennedy; C M Balch
Journal:  Cancer       Date:  1983-06-01       Impact factor: 6.860

View more
  3 in total

Review 1.  Clinical and biological aspects of sentinel node biopsy in malignant melanoma--an update.

Authors:  Isabel Callejo Peixoto; José Meneses e Sousa
Journal:  Clin Transl Oncol       Date:  2005-05       Impact factor: 3.405

2.  How morphometric analysis of metastatic load predicts the (un)usefulness of PET scanning: the case of lymph node staging in melanoma.

Authors:  G S Mijnhout; O S Hoekstra; A van Lingen; P J van Diest; H J Adèr; A A Lammertsma; R Pijpers; S Meijer; G J J Teule
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

3.  Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.

Authors:  F Roka; H Kittler; P Cauzig; C Hoeller; G Hinterhuber; K Wolff; H Pehamberger; E Diem
Journal:  Br J Cancer       Date:  2005-02-28       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.